|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0018787,
umls-concept:C0030705,
umls-concept:C0071097,
umls-concept:C0079809,
umls-concept:C0268000,
umls-concept:C0332307,
umls-concept:C0456389,
umls-concept:C0542341,
umls-concept:C0907402,
umls-concept:C1280500
|
|
pubmed:dateCreated |
2009-4-3
|
|
pubmed:abstractText |
Both insulin and thiazolidinediones (TZDs) are effective in the treatment of hyperglycaemia and amelioration of insulin resistance in type 2 diabetes but have side effects including weight gain and fluid retention. The use of TZDs has been further hampered by the risk of adverse cardiovascular events including heart failure. The present study evaluated the effect of pioglitazone or insulin glargine on cardiac function and size as well as on surrogate markers of fluid retention such as weight, haemoglobin and natriuretic peptides.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-11150629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-12401757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-15616804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-15619076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-16053992,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-16214598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-16376782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-16781359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-17536074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-17848652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-18445302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-18760965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19298680-19029503
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1475-2840
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
15
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19298680-Aged,
pubmed-meshheading:19298680-Atrial Function, Left,
pubmed-meshheading:19298680-Diabetes Mellitus, Type 2,
pubmed-meshheading:19298680-Edema,
pubmed-meshheading:19298680-Electrocardiography,
pubmed-meshheading:19298680-Female,
pubmed-meshheading:19298680-Humans,
pubmed-meshheading:19298680-Insulin,
pubmed-meshheading:19298680-Insulin, Long-Acting,
pubmed-meshheading:19298680-Male,
pubmed-meshheading:19298680-Middle Aged,
pubmed-meshheading:19298680-Myocardium,
pubmed-meshheading:19298680-Organ Size,
pubmed-meshheading:19298680-Pilot Projects,
pubmed-meshheading:19298680-Thiazolidinediones,
pubmed-meshheading:19298680-Ventricular Function, Left
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.
|
|
pubmed:affiliation |
Department of Clinical Sciences, Division of Diabetes & Endocrinology, Lund University, Malmö University Hospital, Malmö, Sweden. mozhgan.dorkhan@med.lu.se
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
